Epigenetics encompasses all of the mechanisms involved in deploying the genetic program for the many processes operating during the lifespan of a cell. These are stable but can be somewhat modified by physiological, pathological conditions, and by the environment. [8] [9] [10] The recent surge in the knowledge of this field is contributing to a better understanding 
INTRODUCTION
Epigenome literally meaning "beyond the genome" is defined as the study of mitotically and meiotically heritable biochemical modifications in gene function that are not dependent on DNA sequence. [1] [2] [3] The key concept is that the epigenome, consisting of chromatin and its modifications, functions as an interface between the inherited genome and the dynamism imposed by the environment, constituting an "epigenetic code" which organizes the chromatin structure on different hierarchal levels. [4, 5] Feinberg terms it as a metastable condition that represents an epigenetic modification, resulting in a new cellular, or tissue homeostatic "set-point" with a new range of gene expression patterns that differ from those of the original state. [6] More recent and accurately defined as "the study of stable genetic modifications that result in changes in gene expression and function without a corresponding alteration in DNA sequence" (http://www. nihroadmap.nih.gov/roadmap15update.asp).
Journal of Advanced Oral Research / Sep-Dec 2015 / Vol. 6 No. 3 of gene-environment interactions, as this additional layer of transcriptional control that regulates gene expression can be exploited for developing newer methods to diagnose and treat the most prevalent human pathologies. [11] 
HISTORICAL PERSPECTIVE
In late 1940's developmental biologist, Conrad Waddington (1905 Waddington ( -1975 introduced the term "epigenetics" derived from the Greek word "epigenesis". [12, 13] He indicated that an epigenetic landscape underlies each developing organism, referring to the existence of a complex network in which genetic interactions, the feedback and "feed forward" relationships among DNA, proteins, and other internal and external biochemical compounds are highly intermingled. [14] In 1975, two papers were published outlining a molecular model for the switching of gene activities, and also the heritability of gene activity or inactivity. [15, 16] More recently, the scope of epigenetics extends to all heritable modifications of genes, e.g., DNA methylation, histone modifications, non-coding RNA, etc., leading to alteration in the expression of specific DNA sequences that vary among different tissues within the same organism. Furthermore, these potential epigenetic modifications can occur throughout the lifetime of the organism, beginning as early as the intra-uterine environment, and can accumulate in tissues and cells over time to modify gene expression patterns and cellular phenotypes in health and disease. It is viewed as a bridge between genotype and phenotype. [17, 18] 
EPIGENETIC MECHANISMS
Evertts et al. reviewed the modern techniques to study more quantitatively the molecular basis of epigenetic regulation, e.g., polymerase chain reaction, pyrosequencing, radiolabeled isotopes, such as [14C] acetate or [3H] acetate, Western blotting, mass spectrometry, and chromatin immunoprecipitation. [19] [20] [21] Five major epigenetic mechanisms are capable of establishing and stabilizing open or closed chromatin structures, thereby regulating transcriptional activity. [22] 1. DNA methylation 2. Post-translationally modified Histones-phorylation, acetylation, and methylation 3. Non-coding RNAs 4. Nucleosome remodelers 5. Differential expression of histone H3 variants.
DNA methylation
This is the most well studied epigenetic modification of DNA in mammals, characterized by covalent methylation of cytosine in CpG dinucleotides, predominantly at 5´ location to a guanosine from S-adenosyl-Lmethionine. [11, [23] [24] [25] [26] In normal cells, DNA methylation occurs predominantly in repetitive genomic regions, including satellite DNA and parasitic elements and endogenous retroviruses. [27] Enzymes there are minimally three DNA methyltransferases, DNMT1, DNMT3a, and DNMT3b, which catalyze the transfer of a methyl group from S-adenosyl-L-methionine to cytosine bases in DNA. DNMT1 is the most abundant methyltransferase in somatic cells, responsible for the maintenance of DNA methylation.
[28] DNMT3a and DNMT3b are required for the de novo methylation that occurs in the genome following embryo implantation. [29, 30] However, several studies show that all three DNMTs not only cooperate, but also may participate in de novo and maintenance methylation functions. [7, 31, 32] No known DNA demethylases have so far been identified. Transcriptional repression is mediated by methyl-CpGbinding domain (MBDs) proteins such as MeCP2 that recognize methylated cytosines, and the recruitment of histone deacetylases (HDAC), co-repressor Sin3a and Brahma in the SWI/SNF complex. [5, 33] 
Mechanisms
• DNA methylation directly inhibits the binding of transcription factors such as AP-2, c-Myc/Myn, E2F and NFkB to their binding sites within promoter sequence [34] • A binding of specific proteins for m5CpG dinucleotides to methylated DNA is the second mode of repression [35] The passive process takes place in the absence of methylation of newly synthesized DNA strands by DNMT1 during several replication rounds. [36] However, the active process occurs via active removal of the methyl group. [34, 37] 
Histone modifications
Modifications have been detected in over 60 different residues on histones, and the NH 2 -terminal "tail" domains are the most heavily modified portions. [38] There are approximately eight types of modifications found on histones, of which acetylation, performed by histone acetyltransferase (HATs) enzymes, is the most extensively researched and is generally associated with active gene transcription, while methylation, performed by histone methyltransferases (HMTs), may be linked to activation (i.e., H3K4, H3K36, and H3K79) or repression (i.e., H3K9, H3K27, and H4K20), depending on the conditions or residue modified. [7, 38, 39] Histone acetylation is regulated by opposing actions of HATs and HDACs.
Enzymes there exist three major families of HATs that mediate transcriptional activation and target H3 or H4. [40] The MYST family contains the highly conserved MYST domain. Both members of the GNAT and the CBP/p300 family contain the bromodomain that is known to be associated with chromatin binding and can function as global coactivators. [41] HDACs remove acetyl groups and are generally related to gene silencing. [2, [42] [43] [44] [45] Class I HDACs (HDACs 1, 2, 3, and 8) are found predominantly in the nucleus. Class II HDACs (HDACs 4, 5, 6, 7, 9, and 10) shuttle between the nucleus and the cytoplasm. Both Class I and Class II HDACs have tissue-specific expression profiles. HDACs 1, 2, and 3 are ubiquitously expressed in the various immune tissues. [5, 46] Class III HDACs (Sirt1-Sirt7) are important in DNA repair and anti-apoptotic functions. HDAC11 has been classified as its own class, HDAC Class IV, since it has properties of both Class I and Class II HDACs. [5] Histone methylation mediates both silencing and activation depending on the substrate available, for example lysine or arginine. [47, 48] Lysines can be mono-(m), di-(m2), and tri-methylated (m3), whereas arginine can be mono-or di-methylated. Methylation of arginines differs from that of lysines as it is a very transient modification but carries significant implications in inflammation. [5] 14 different histone residues can be methylated on histones H3 and H4. [49, 50] Enzymes methylation of histones is carried out by HMT and demethylation by histone demethylases (HDM) such as members of the Jumonji protein family [ Table 1 ]. [2, 51] RNA silencing MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate the expression of target genes at the post-transcriptional level. The RNA-induced silencing complex (RISC) incorporates short RNA duplexes and binds to the 3′ untranslated region (3′UTR) of specific messenger RNAs for subsequent degradation or translational repression. [2, 7] The sequence-specific base pairing of miRNAs with 3′UTR of target messenger RNA within the RISC results in target messenger RNA degradation or inhibition of translation. [52] miRNAs are expressed in a tissue-specific manner and control a wide array of biological processes including cell proliferation, apoptosis, and differentiation. About 30% of all human genes are estimated to be potential miRNA targets. [53, 54] Recent investigations implicated miRNAs in the regulation of development, differentiation, and disease. [55, 56] Coordination within the transcription machinery The circumstantial and direct evidence is supportive of a connection between histone acetylation and DNA methylation. [23, [57] [58] [59] [60] [61] [62] However, there is no consensus on which epigenetic mechanism initiates and steers this communication.
The exposed methylation sites attract methyl-binding proteins, the MBDs proteins, e.g., Kaiso, MeCP2, etc., which read methylation marks to affect chromatin condensation by recruiting HDACs that covalently modify the tails of histone proteins. [63, 64] Histone modification results in gene silencing and chromatin compaction. [2, 58, 65] The histone H3 N-terminal tail with an unmethylated lysine 4 (H3K4) is required for DNA methylation. [66] In addition, tri-methylation of histone H3 on lysine 9 (H3K9me3) participates in DNA methylation mediated by DNMT1. The NP95 protein, which contains SET-, Ring-, and Tudor domains, is responsible for linking DNMT1 with DNA and histone H3 methylation (H3K9me3). [2, 67] Changes in methylation status can also regulate miRNA expression as well, which in turn, modulates post- transcriptional gene expression and a plays a critical role in gene expression reprogramming during development and differentiation. [11, 68, 69] In addition, miRNAs can also modulate epigenetic regulatory mechanisms inside a cell by targeting enzymes responsible for DNA methylation (DNMT3A and DNMT3B) and histone modifications (EZH2). [70, 71] 
EPIGENETIC REGULATION OF GENE EXPRESSION
Through repressive methylation, histone complexes, and chromatin conformation, epigenetic mechanisms can establish quantitative thresholds for the induction of gene expression within all this diversity outlined above. These may be manifested as (a) the strength of stimulus needed to induce expression of a gene in a single cell, (b) the probability of gene expression in a population of cells or tissue, (c) the delay before detectable expression is induced, (d) the peak level of expression attained, and/or (e) linked patterns of gene expression. [72] 
E P I G E N E T I C S , I N F L A M M AT I O N , A N D CARCINOGENESIS: MECHANISMS CENTRAL TO MOST COMMON HUMAN PATHOLOGIES
It is clear that the epigenetic state is a central regulator of cellular development and activation. The importance of the epigenome in the pathogenesis of common human diseases is likely to be as significant as that of traditional genetic mutations. A comprehensive review of the available evidence suggests that the epigenome modulates the risk of many most prevalent, chronic human pathologies through associations with a multitude of risk factors for the disease. [73, 74] Shear stress (blood flow), hypoxia, cytokines, and entry into the cell cycle and their ability to act as molecular integrators of environmental signals internal and external to the cell forms the basis for this fundamentally new, epigenetic perspective on the human cardiovascular disease. [75] Similarly, the ambient or prior hyperglycemia led to sustained up-regulation of the NFκB-p65 gene leading to increased H3K4m1, and other epigenetic effects, including the suppression of H3K9m2 and H3K9m3 methylation on the p65 promoter, lead to sustained activation of pro-inflammatory pathways, which are likely to participate in the progression of diabetic complications. [76] The evidence demonstrates that a number of gene-environment interactions modulate the risk for diabetes, metabolic syndrome, and cardiovascular disease through their associations with multiple risk factors, such as obesity, lipid levels in the fasting and post-prandial state, and markers of inflammation. [73] Armenante et al. studied two human breast carcinoma cell lines, MDA-MB-231, in which the interleukin-6 (IL-6) gene is expressed, and, MCF-7, in which the IL-6 message is undetectable by Northern blot assay even in the presence of inducers. The authors demonstrated that treatment of MCF-7 cells with an agent which reduces DNA methylation correlates with IL-6 gene hypomethylation and increases the level of its expression. [77] Sullivan et al. demonstrated that epigenetic modifications of the tumor necrosis factor-alpha (TNF-α) locus occur both developmentally and in response to acute stimulation. The authors stated DNA demethylates early in development, beginning with the hematopoietic stem cell. In each case, manipulation of these epigenetic variables altered the ability of the cell to express TNF-α. These findings may have relevance for inflammatory disorders in which TNF-α is overproduced. [78] These data indicated that DNA methylation may be one mechanism through which T-cell cytokine gene expression is regulated.
Epigenetic changes set the stage for alterations in gene expression and have been identified as important components of carcinogenesis. [79, 22] Hypomethylation is consistent with the overall increased transcriptional activity seen in most tumors. However, loss of DNA methylation, which often occurs at sequences which are unstable, is likely related to increased tumor frequency due to chromosomal instability, and has been considered as the earliest epigenetic change from a normal to a pre-malignant cell. However, the expression of certain oncogenes appears to be directly activated by hypomethylation, whereas hypermethylation of tumor suppressor genes can also be seen. Examples of promoter DNA hypermethylation and chromatin hypoacetylation, which result in the silencing of tumor suppressor genes, include p16 (also known as cyclin-dependent kinase inhibitor 2A) and sMutL protein homolog 1. [24, 80, 81] Global hypomethylation of genomic DNA is observed in numerous tumor cells and is responsible for overexpression of proto-oncogenes, growth factors, and genes which via their protein products are involved in cancer cell proliferation, invasion, and metastasis. [82] DNMT3B isoforms contribute to hypermethylation and hypomethylation of genomic DNA promoting development, invasion, and metastases of cancer [ Table 2 ]. [35] 
PERIODONTAL INFLAMMATION -THE EPIGENETIC VIEWPOINT
Periodontal diseases, a series of infections of the periodontal tissues which eventually can lead to loss of teeth, is a form of aberrant inflammation resulting from a complex biofilm of friendly commensal and periodontopathic bacteria and their products, triggering the human inflammatory response. Traditionally, periodontitis was thought to be strictly environmental in origin. However as host susceptibility may be defined in terms of genetic variation (as explained in preceding sections about immune-inflammatory disorders), a relatively recent focus in periodontology has been to quantify genetic risk and identify specific gene variants that determine disease susceptibility.
Genetic influence on chronic inflammatory diseases is well-documented and beyond doubt. [83] Tissuespecific chronic inflammation is characterized by an epigenetic state with enrichment of hypo-acetylated histones and hyper-methylated CpGs that contribute to a persistent inflammatory response. Prostaglandinendoperoxide synthase-2 promoter methylation levels from periodontally inflamed gingival biopsies showed significant increase when compared with non-inflamed biopsy samples, suggesting that methylation status is associated with chronic inflammation. [5, 84] The plaque microorganisms gain significant survival advantages as these specific changes shut down genes involved in local defenses and healing (facilitating colonization and dissemination), in the regulation of vascular endothelial function (decreasing tissue perfusion and increasing inflammatory damage), and in host metabolism (providing bacteria with more carbohydrates to fuel growth and reproduction). Furthermore, there is evidence that the early inflammatory response to gingivitis influences the predominance of period pathogens. [85] Periodontitis is not just a chronic inflammatory disease, but its persistent nature could also exert a significant systemic impact on health, such as atherosclerosis, aspiration pneumonia, diabetes, adverse pregnancy outcomes, and rheumatoid arthritis. [86] [87] [88] [89] The possibility that differential methylation induces changes in the host genome that may contribute to the disease state provides an additional avenue for research into the biologic phenotype underlying the clinical presentation of periodontitis. The ''biologic systems model'' approach insists on looking out for subject-level exposures, including the genetic and epigenetic components, as well as establishing the biologic phenotype to determine the clinical phenotype of the periodontal disease. Theoretically, understanding the biologic bases including genetic and epigenetic influences in addition to our current knowledge about the etiopathogenesis underlying different clinical phenotypes of periodontal disease should aid us in establishing prognosis and developing novel and more personalized treatments. [90, 91] 
REVERSIBILITY OF EPIGENETIC EVENTS AS A THERAPEUTIC TARGET
Since epigenetic modification plays such an important role in cancer, novel therapeutic strategies are being developed that are based on the reversal of DNA methylation and the inhibition of histone deacetylation. [92] Taken together, these studies prove that RNAi, when adequately used, can foster tissue regeneration. [93, 94] Gadd45a mediated gene-specific active demethylation occurs during osteogenic differentiation of adiposederived mesenchymal stem cells. [34] Recent research found that KDM4B and KDM6B, two gene-activating enzymes, can promote stem cells' differentiation into bone cells by removing methyl markers from histone proteins. This group's research could pave the way toward identifying potential therapeutic targets for stem cell-mediated regenerative medicine, as well as the treatment of bone disorders such as osteoporosis, the most common type of metabolic bone disease and craniofacial bone regeneration. [95] Although epigenetic therapy is useful in treating some epigenetic disorders, adverse effects have been reported for many epigenetic drugs. The ability of these drugs to be incorporated into DNA raises concerns regarding their potential toxic effect on normal cells.
CONCLUSION: FUTURE PROSPECTS AND CHALLENGES
The epigenetic revolution that has come about in the field of biology during the last few decades has challenged the long-held traditional view of the genetic code being the key determinant of cellular gene function and its alteration being the major cause of human diseases. Advances made in the field of epigenetics have led to the realization that the packaging of the genome is potentially as important as the genome itself in regulating the essential cellular processes required for preserving the cellular identity and also in giving rise to various disease states. Deeper understandings of the global patterns of these epigenetic modifications and their corresponding changes in cancer have enabled the design of better treatment strategies. Similarly, a combinatorial approach utilizing different epigenetic therapeutic approaches along with standard chemotherapy holds significant promise for successful treatment of these medical and oral chronic pathologies.
